 | Richard A C HughesShow email addressCentre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK | Department of Neuromuscular Diseases, UCL Queen Square ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Richard A C Hughes:Expert Impact
Concepts for whichRichard A C Hugheshas direct influence:Plasma exchange,Chronic inflammatory,Intravenous immunoglobulin,Multiple sclerosis,Barré syndrome,Inflammatory demyelinating,Guillainbarré syndrome,Guillain‐barré syndrome.
Richard A C Hughes:KOL impact
Concepts related to the work of other authors for whichfor which Richard A C Hughes has influence:Neuropathic pain,Multiple sclerosis,Chronic inflammatory,Barré syndrome,Intravenous immunoglobulin,Plasma exchange,Campylobacter jejuni.
KOL Resume for Richard A C Hughes
| Year | |
|---|---|
| 2021 | Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK |
| 2020 | Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK |
| 2019 | Department of Neuromuscular Diseases, University College London, London WC1N 3BG, UK |
| 2018 | MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK |
| 2017 | University College Department of Neurology, Institute of Neurology London UK |
| 2016 | MRC Centre for Neuromuscular Diseases Institute of Neurology University College London London UK |
| 2015 | MRC Centre for Neuromuscular Diseases Institute of Neurology University College London LondonUK |
| 2014 | MRC Centre for Neuromuscular diseases, UCL Institute of Neurology, London, UK. |
| 2013 | National Hospital for Neurology and Neurosurgery, /INS;London/INS;,/INS; UK |
| 2012 | Institute of Neurology, University College London MRC Neuromuscular Disease Centre London UK |
| 2011 | Correspondence to: MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK MRC Centre for Neuromuscular Disease, Institute of Neurology, University College London, United Kingdom |
| 2010 | Department of Clinical Neuroscience, King's College London, London, UK Cochrane Neuromuscular Disease Group, MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, United Kingdom |
| 2009 | JW Griffin is the Editor-in-Chief of Nature Clinical Practice Neurology. RAC Hughes is Emeritus Professor of Neurology at King's College London and Visiting Professor of Neurology at University College London, London, UK. Department of Clinical Neuroscience, King's College London, London National Hospital for Neurology and Neurosurgery, |
| 2008 | Department of Clinical Neuroscience, King's College London, Institute of Psychiatry, London, UK |
| 2007 | Department of Clinical Neuroscience, King's College London School of Medicine, Guy's Campus, London SE1 1UL, UK |
| 2006 | Department of Neurology, Guy's, King's and St Thomas’ School of Medicine, London, UK Members of Joint Task Force of the EFNS and the PNS |
| 2005 | Department of Clinical Neuroscience, Guy’s Campus, King’s College, London SE1 1UL, UK Emeritus Professor of Neurology, University College London School of Medicine and The National Hospital for Neurology and Neurosurgery, London, United Kingdom Professor of Neurology and Roy E. and Merle Meyer Professor of Neuroscience, Mayo Clinic College of Medicine Head of the Peripheral Neuropathy Research Center and Consultant in Neurology, Mayo Clinic, Rochester, Minnesota |
| 2004 | Department of Clinical Neurosciences, Guy's, King's and St Thomas' School of Medicine, London SE1 1 UL, UK |
| 2003 | Department of Neuroimmunology, Guy’s, King’s and St Thomas’ School of Medicine, London, UK |
| Concept | World rank |
|---|---|
| placebo observational studies | #1 |
| gbs reasons | #1 |
| resultscochrane reviews | #1 |
| myelinprotein | #1 |
| ond gbs | #1 |
| task force cidp | #1 |
| weeks followup patients | #1 |
| sfv gangliosides | #1 |
| enhanced glucose control | #1 |
| january 1966 | #1 |
| corticosteroids risk ratio | #1 |
| axonal polyneuropathy evidence | #1 |
| exchange guillain‐barré | #1 |
| cambs | #1 |
| guillainbarré corticosteroids | #1 |
| immunotherapy chronic inflammatory | #1 |
| distance doctors | #1 |
| lif ean | #1 |
| cidp acquired disorder | #1 |
| mycophenolate immunomodulatory drug | #1 |
| patient diseases | #1 |
| removal igm antibody | #1 |
| presence gm1 hapten | #1 |
| ivig oral prednisone | #1 |
| peripheral nerves cns | #1 |
| 2011 trials | #1 |
| summer epidemics gbs | #1 |
| supportive treatment | #1 |
| corticosteroid immunosuppressive agents | #1 |
| übereinstimmung läßt | #1 |
| trial tripterygium polyglycoside | #1 |
| snrs edss | #1 |
| ivig produces | #1 |
| distribution human nervous | #1 |
| ean cidp | #1 |
| neighbouring nerve fibres | #1 |
| relationship guillain‐barré syndrome | #1 |
| gbs gbs sera | #1 |
| weeks disability grade | #1 |
| corticosteroids topic adolescent | #1 |
| disability score proportion | #1 |
| complex unfamiliar tasks | #1 |
| beta restricted response | #1 |
| lecithin antibody titers | #1 |
| cederived lymphocytes | #1 |
| immunoglobulin deposition myelin | #1 |
| summarised retrospective | #1 |
| perivascular cells endoneurium | #1 |
| lymphoma peripheral nervous | #1 |
| absence systemic vasculitis | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Richard A C Hughes
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews
[ PUBLICATION ]
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic progressive or relapsing and remitting disease that usually causes weakness and sensory loss. The symptoms are due to autoimmune inflammation of peripheral nerves. CIPD affects about 2 to 3 per 100,000 of the population. More than half of affected people cannot walk unaided when symptoms are at their worst. CIDP usually responds to treatments that reduce inflammation, but there is disagreement about ...
| Known for Treatment Cidp | Chronic Inflammatory | Observational Studies | Placebo Adverse Events | Plasma Exchange |
BACKGROUND: Guillain-Barré syndrome is an acute symmetric, usually ascending and usually paralysing illness, due to inflammation of peripheral nerves. It is thought to be caused by autoimmune factors, such as antibodies. Plasma exchange removes antibodies and other potentially injurious factors from the blood stream. It involves connecting the patient's blood circulation to a machine which exchanges the plasma for a substitute solution, usually albumin. Several studies have evaluated ...
| Known for Plasma Exchange | Barré Syndrome | Supportive Treatment | Disability Grade | Disease Onset |
BACKGROUND: Guillain-Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune diseases. This is an update of a review first published in 2001 and previously updated in 2003, 2005, 2007 and 2010. Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ...
| Known for Intravenous Immunoglobulin | Ivig Treatment | Guillain‐barré Syndrome | Recovery Gbs | Review Trials |
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy is a disease causing progressive or relapsing and remitting weakness and numbness. It is probably due to an autoimmune process. Immunosuppressive or immunomodulatory drugs would be expected to be beneficial.
OBJECTIVES: We aimed to review systematically the evidence from randomised trials of cytotoxic drugs and interferons other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory ...
| Known for Chronic Inflammatory | Plasma Exchange | Immunomodulatory Treatment | Year Participants | Azathioprine Interferon |
BACKGROUND: Guillain-Barré syndrome is an acute paralysing disease caused by peripheral nerve inflammation. This is an update of a review first published in 2001 and last updated in 2008.
OBJECTIVES: To assess the effects of plasma exchange for treating Guillain-Barré syndrome.
SEARCH METHODS: We searched the Cochrane Neuromuscular Disease Group Specialized Register (14 June 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), MEDLINE (January 1966 to June ...
| Known for Plasma Exchange | Guillain‐barré Syndrome | 649 Participants | Supportive Treatment | Topic Recovery |
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing and remitting paralysing illness probably due to an autoimmune response which should benefit from corticosteroids. Non-randomised studies suggest that corticosteroids are beneficial. Two commonly used corticosteroids are prednisone and prednisolone. Both are usually given as oral tablets. Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is ...
| Known for Chronic Inflammatory | Corticosteroids Prednisone | Treatment Cidp | Monthly Dexamethasone | 12 Weeks |
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome
[ PUBLICATION ]
BACKGROUND: Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown.
OBJECTIVES: To review systematically the evidence from randomised controlled trials for pharmacological agents other than plasma exchange, intravenous immunoglobulin and corticosteroids.
SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group Specialized Register (5 July 2010), the ...
| Known for Plasma Exchange | Pharmacological Treatment | Intravenous Immunoglobulin | Guillain Barré | Difference Outcome |
BACKGROUND: Duloxetine is a balanced serotonin and noradrenaline reuptake inhibitor licensed for the treatment of major depressive disorders, urinary stress incontinence and the management of neuropathic pain associated with diabetic peripheral neuropathy. A number of trials have been conducted to investigate the use of duloxetine in neuropathic and nociceptive painful conditions. This is the first update of a review first published in 2010.
OBJECTIVES: To assess the benefits and harms ...
| Known for Chronic Pain | Duloxetine Treatment | 95 Nntb | Diabetic Neuropathy | Studies Low Risk |
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing and remitting paralysing illness probably due to an autoimmune response which should benefit from corticosteroids. Non-randomised studies suggest that corticosteroids are beneficial. Two commonly used corticosteroids are prednisone and prednisolone. Both are usually given as oral tablets. Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is ...
| Known for Chronic Inflammatory | Treatment Cidp | Randomised Trials Corticosteroids | Prednisone Prednisolone | Monthly Dexamethasone |
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome
[ PUBLICATION ]
BACKGROUND: Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and this update in 2013.
OBJECTIVES: To review systematically the evidence from randomised controlled trials (RCTs) for pharmacological agents other than plasma exchange, intravenous immunoglobulin and corticosteroids.
SEARCH METHODS: On 28 August 2012, we ...
| Known for Plasma Exchange | Pharmacological Treatment | Intravenous Immunoglobulin | Guillain‐barré Syndrome | Weeks Corticosteroids |
BACKGROUND: Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by peripheral nerve inflammation. This is an update of a review first published in 2001 and last updated in 2012.
OBJECTIVES: To assess the effects of plasma exchange for treating GBS.
SEARCH METHODS: On 18 January 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, and Embase. We also searched clinical trials registries.
SELECTION CRITERIA: Randomised and quasi-randomised ...
| Known for Plasma Exchange | Guillain‐barré Syndrome | Topic Recovery | Muscle Strength | Randomized Controlled |
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy is an uncommon progressive or relapsing paralysing disease caused by inflammation of the peripheral nerves. If the hypothesis that it is due to autoimmunity is correct, removal of autoantibodies in the blood by plasma exchange should be beneficial.
OBJECTIVES: To evaluate the efficacy of plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.
SEARCH STRATEGY: We searched the Neuromuscular Disease ...
| Known for Plasma Exchange | Inflammatory Demyelinating | Improvement Weeks | Rapid Deterioration | Polyradiculoneuropathy Chronic |
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an uncommon progressive or relapsing paralysing disease caused by inflammation of the peripheral nerves. If the hypothesis that it is due to autoimmunity is correct, removal of autoantibodies in the blood by plasma exchange should be beneficial.
OBJECTIVES: To evaluate the efficacy of plasma exchange in CIDP.
SEARCH METHODS: We searched the Cochrane Neuromuscular Disease Group Specialized Register (14 May ...
| Known for Plasma Exchange | Chronic Inflammatory | Trials Trial Authors | Intravenous Immunoglobulin | Rapid Deterioration |
OBJECTIVES: The ability of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) to detect malignant change in plexiform neurofibromas from patients with neurofibromatosis 1 (NF1) was evaluated.
METHODS: Eighteen NF1 patients who presented with pain, increase in size, or neurological deficit associated with a plexiform neurofibroma were assessed. Magnetic resonance imaging determined the site and extent of the lesion. Qualitative(18)FDG PET was performed and the standard ...
| Known for Plexiform Neurofibromas | 18fdg Pet | Nerve Sheath | Malignant Peripheral | Emission Tomography |
